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Eprinomectin, a semisynthetic compound of the avermectin family, is marketed as a topical pour-on 
formulation for use in cattle at a dosage of 500 µg/kg.1 
Eprinomectin has been used extensively to control endo- 
parasites and ectoparasites of dairy animals because 
it has a relatively high maximum residue limit, which 
suggests that eprinomectin can be used safely in lactat-
ing animals with no milk-withdrawal time.2,3 Moreover, 
use of pour-on formulations of anthelmintics decreases 
the risk of injury for humans and animals, compared 
with that for use of injectable products, and is particu-
larly convenient for farmers because they can apply the 
product easily.4
A paucity of data is available on the efficacy of 
anthelmintics used in donkeys because donkeys are 
often a neglected species for studies in domestic ani-
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mals. Classes of drugs used in horses and ruminants 
are commonly extrapolated for use in donkeys with-
out optimization of dosing regimens and determina-
tion of pharmacokinetic and pharmacodynamic prop-
erties. Because of the lack of drugs approved for use 
in donkeys, anthelmintics licensed for use in horses or 
ruminants are used at the same dosages for treatment 
of parasitic infections in donkeys. It has been reported 
that donkeys have a greater capacity to metabolize cer-
tain drugs, compared with the capacity for horses; thus, 
higher dosages or shorter intervals could be required 
to maintain effective drug concentrations in donkeys.5–8
Donkey milk is gaining popularity for consump-
tion by humans in some countries, such as Italy, France, 
and Belgium, because it is the milk closest in composi-
tion to human milk and is ideal for feeding infants.9 
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AbbreviAtions
AUC Area under the plasma concentration–time 
   curve
Cmax Maximum plasma concentration
FECR Fecal egg count reduction
HPLC High-performance liquid chromatography
MRT Mean residence time
Tmax Time to reach maximum plasma concen- 
   tration
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Furthermore, there is an increasing interest in rais-
ing donkeys because of the development of their use 
in leisure activities and onotherapy (a type of pet- or 
animal-assisted treatment popular in Italy that involves 
the use of donkeys) and, in particular, the rediscovery 
of donkey milk as a food source for children affected by 
allergies to cow milk.10 To our knowledge, there have 
been no data reported regarding the pharmacokinetics 
and efficacy of eprinomectin against parasites in don-
keys. Thus, the purpose of the study reported here was 
to determine the potential of topical administration 
as a treatment route in donkeys and to investigate the 
plasma disposition and anthelmintic efficacy of eprino-
mectin in donkeys after topical administration at a dos-
age used in cattle (0.5 mg/kg). Moreover, hair concen-
tration was determined at the application sites and far 
from the application sites after topical administration 
of eprinomectin.
Materials and Methods
Animals—Twelve donkeys (8 nonpregnant females 
and 4 males) with a mean ± SD age of 5.0 ± 1.5 years 
were used in the study. Donkeys weighed between 128 
and 380 kg; the body weight of each donkey was esti-
mated 1 day before treatment by use of the nomogram 
proposed by a United Kingdom–based charity facility 
for donkeys.11 The donkeys had a history of grazing on 
pasture contaminated with equine nematode parasites, 
but they were kept indoors and fed hay and concen-
trated feed formulated for horses during the study. The 
donkeys had not been treated with any anthelmintics 
during the 9 months preceding the study. Fecal exami-
nations (fecal egg counts for each donkey and pooled 
coprocultures) performed before the beginning of the 
study revealed counts of > 150 eggs/g of feces for in-
dividual donkeys and a high prevalence of intestinal 
nematodes (Cyathostomum spp, Poteriostomum spp, Tri-
odontophorus spp, and Strongylus spp) in all donkeys. 
The donkeys received an identification tag and were 
housed communally in an indoor pen until the study. 
Water was provided ad libitum throughout the course of 
the study. The study was approved by the Animal Ethics 
Committee of the University of Naples Federico II.
Treatments and sample collection—Extralabel ad-
ministration of a pour-on formulation of eprinomectin 
licensed for use in cattle was used on the 12 donkeys in 
the present study. The dose was calculated on the basis 
of the body weight of each donkey. The pour-on for-
mulation of eprinomectina was administered topically 
at a dosage of 0.5 mg/kg along the dorsal midline of the 
donkeys. Pharmacokinetic assessment was performed 
for 8 donkeys (4 males and 4 females). Heparinized blood 
samples were collected via jugular venipuncture prior to 
drug administration (time 0) and then at 1, 2, 4, 8, 12, 16, 
24, 32, 48, 72, 96, and 120 hours and 6, 8, 10, 12, 15, 20, 
25, 30, 35, and 40 days after administration.
Hair samples (> 0.05 g) were also collected prior 
to drug administration and then at 24, 48, 72, 96, and 
120 hours and 6, 8, 10, 12, 15, 20, 25, 30, 35, and 40 
days after administration. Hair samples were collected 
with scissors from the application site and at a loca-
tion far from the application site (ie, the ventral part of 
the thorax of each donkey) and used to determine con-
centrations in the hair attributable to administration of 
eprinomectin. To prevent cross-contamination, gloves 
were changed and scissors were washed with ethanol 
after collection of each hair sample. Blood samples were 
centrifuged at 2,000 X g for 30 minutes, and plasma was 
harvested and transferred to plastic tubes. All plasma and 
hair samples were stored at –20°C inside plastic tubes and 
bags, respectively, until analyzed to determine the drug 
concentration.
Analytic procedures—A stock solution (100 µg/
mL) of a pure standard of eprinomectinb was prepared 
with acetonitrileb as the solvent. This stock solution 
was diluted to standard solutions of 5, 10, 100, 200, 
and 500 ng/mL and to 0.5, 1, 5, 10, and 50 µg/mL for 
plasma and hair samples, respectively. Standard solu-
tions were used to provide calibration as standard 
curves and were added to drug-free plasma and hair 
samples to determine recovery.
Plasma concentration of eprinomectin was ana-
lyzed via HPLC with fluorescence detection following 
a solid-phase extraction procedure performed in ac-
cordance with a method described elsewhere.12 Hair 
samples were analyzed via HPLC with a liquid-liquid 
phase extraction procedure adapted from the method 
described in another study.13
Briefly, drug-free plasma samples (1 mL) were 
spiked with the pure standard of eprinomectin to 
achieve final concentrations of 0.25, 0.5, 1, 10, 25, and 
50 ng/mL Plasma samples (spiked and unknowns) were 
combined with 50 µL of internal standard (moxidectinb 
[250 ng/mL]) and then mixed with 1 mL of acetonitrile. 
The solvent-sample mixture was mixed for 5 minutes 
and then centrifuged at 10,000 X g for 10 minutes. Su-
pernatant was transferred to a C
18
 solid-phase extrac-
tion cartridgec previously conditioned with 2 mL of 
methanol and 2 mL of deionized water. The cartridge 
was washed with 2 mL of a water:methanol mixture (3:1 
[vol/vol]) and dried under vacuum for 1 hour. Analytes 
were eluted with 3 mL of methanol and concentrated to 
dryness at 45°C in a sample concentrator.d Reconstitu-
tion was performed by use of 100 mL of a solution of 
N-methylimidazole in acetonitrile (1:1 [vol/vol]). De-
rivatization was initiated by the addition of 150 mL of 
trifluoroacetic anhydride solution in acetonitrile (1:2 
[vol/vol]). The samples were vortexed for 10 seconds, 
and 50 µL of glacial acetic acidb then was added. Sam-
ples were again vortexed for 10 seconds, and samples 
then were incubated at 65°C for 30 minutes. After incu-
bation, samples were cooled at 4°C for 3 minutes, and 
an aliquot (50 µL) of this solution was injected into 
the chromatograph. The mobile phase consisted of ace-
tonitrile, methanol, and ultrapure water (65:32:3 [vol/
vol/vol]) and was delivered via a pumpe at a flow rate 
of 1 mL/min. A nucleosil C18 analytic column
f (particle 
size, 3 µm; dimension, 150 X 4.6 mm) with nucleosil C18 
guard columnf was used for analysis of the analytes. Fluo-
rescence detectione was performed at an excitation wave-
length of 365 nm and an emission wavelength of 475 nm.
The analytic methods used for eprinomectin in 
plasma and hair samples were validated prior to the 
start of the study. The analyte was identified with the 
retention times of the pure reference standard. Recov-
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eries of the analytes were measured by comparison of 
the peak areas from 6 spiked plasma and hair samples 
with the areas resulting from injection of standards pre-
pared in acetonitrile. The limit of detection and limit of 
quantification were determined for the HPLC method. 
The limits were determined on the basis of the SD and 
slope of the curve at the lowest concentrations. Calibra-
tion curves were fitted by use of 6 concentrations that 
ranged from 0.25 to 50 ng/mL for plasma and 0.5 to 50 
µg/mL for hair.
Parasitologic analysis (fecal examinations and 
anthelmintic efficacy)—Fecal samples were obtained 
from the rectum of each of the 12 donkeys 3 days be-
fore the start of the study, on day 0, and on days 7, 14, 
21, 28, 35, 42, 49, and 56 after treatment. Fecal samples 
were stored in a refrigerator at 4°C as proposed in an-
other study.14 Fecal egg counts were performed within 
4 hours after sample collection. Fecal egg counts for 
individual donkeys were determined via a modified 
McMaster technique with a sensitivity of 10 eggs/g of 
feces by use of a sucrose flotation solution (specific 
gravity, 1.250).15
Individual fecal samples obtained on each day of 
sample collection were incubated at 27°C for 7 to 10 
days for larval identification. Only fecal samples col-
lected 3 days before the start of the study were pooled 
for analysis. Third-stage larvae were identified by use 
of the morphological keys proposed by the Ministry 
of Agriculture, Fisheries and Food.15 When a pooled 
coproculture had ≤ 100 third-stage larvae, all were 
identified; however, when a pooled coproculture had 
> 100 third-stage larvae, only 100 were identified.
To determine the efficacy of eprinomectin against 
intestinal strongyles at each day of sample collection, 
the mean number of eggs per gram of feces was calcu-
lated in accordance with guidelines established by the 
World Association for the Advancement of Veterinary 
Parasitology.16,17 For each donkey, the percentage effi-
cacy was calculated in terms of FECR at each day of 
sample collection by use of the following equation:
FECR = ([mean EPG before treatment – mean EPG  
after treatment]/mean EPG before treatment) X 100
where EPG is the number of eggs per gram of feces.
Pharmacokinetic and statistical analysis of 
data—The plasma concentration versus time curves 
obtained after each treatment in individual donkeys 
were fitted with a software program.g Pharmacoki-
netic parameters for each donkey were analyzed via 
noncompartmental model analysis for topical admin-
istration. The Cmax and Tmax were obtained from 
the plotted plasma concentration–time curve in each 
donkey. The trapezoidal rule was used to calculate 
the AUC, and MRT from 0 to infinity was calculated 
by use of the following equation:
MRT
0–∞
 = AUMC
0–∞
/AUC
0–∞
where AUMC
0–∞
 is the area under the moment curve 
from 0 to infinity and AUC
0–∞
 is the AUC from 0 to 
infinity. Terminal t
1/2
 was calculated as t
1/2λz = –ln(2)/λz, 
where λz is the first-order rate constant associated with 
the terminal (log-linear) portion of the curve.
Results
The donkeys were observed throughout the study. 
No adverse reactions were observed in any of the don-
keys treated with the eprinomectin pour-on formula-
tion, and no licking behavior was observed. The ana-
lytic procedures and HPLC analysis of eprinomectin 
Figure 1—Mean ± SD plasma concentrations of eprinomectin on 
semilogarithmic (A) and linear (B) scales for 8 donkeys at various 
times after topical administration (0.5 mg/kg) of a pour-on formu-
lation licensed for use in cattle. Day of eprinomectin administra-
tion was designated as day 0.
Parameter Mean 6 SD
t1/2λz (d) 6.33 6 0.90
Cmax (ng/mL) 14.17 6 5.98
Tmax (d) 3.38 6 0.74
AUC (ng•d/mL) 129.44 6 36.69
AUMC (ng•d2/mL) 1,121.27 6 250.20
MRT (d) 8.95 6 1.78
t1/2λz = Terminal t1/2. AUMC = Area under the moment curve.
Table 1—Mean ± SD pharmacokinetic parameters for eprinomec-
tin in 8 donkeys after topical administration (0.5 mg/kg) of a pour-
on formulation licensed for use in cattle.
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were validated. Mean recovery of eprinomectin from 
plasma was 88.91% with a relative SD < 10%. The limit 
of detection and limit of quantification for eprinomec-
tin were 0.019 and 0.21 ng/mL, respectively. The in-
terassay and intra-assay precision of the extraction and 
chromatography procedures were evaluated by process-
ing on different days 6 replicate aliquots of drug-free 
donkey plasma samples that contained known amounts 
of eprinomectin. The precision determined at each con-
centration was < 15% of the coefficient of variation, and 
accuracy ranged from 95% to 102%.
Pharmacokinetic parameters of eprinomectin af-
ter topical administration (0.5 mg/kg) were summa-
rized (Table 1). Mean plasma concentration versus 
time curves were plotted on semilogarithmic and linear 
scales (Figure 1). In addition, concentrations of epri-
nomectin in hair samples collected from the applica-
tion site and far from the application site were plotted 
(Figure 2). The Cmax was 14.17 ng/mL, and Tmax was 
3.38 days. The AUC and MRT of eprinomectin were 
129 ng•d/mL and 8.95 days, respectively.
All donkeys shed strongyle eggs in their feces on 
the day of treatment (day 0). The individual and arith-
metic mean of strongyle egg counts and FECRs at the 
various times of sample collection were summarized 
(Table 2). The mean strongyle egg count on day 0 was 
1,361 eggs/g of feces (range, 200 to 3,190 eggs/g of fe-
ces). After treatment, 1 donkey was shedding 10 eggs/g 
of feces by day 21. By day 35, 3 donkeys were shedding 
eggs, and by day 49, 4 donkeys were shedding stron-
gyle eggs. However, FECR remained high throughout 
the study period. The FECR was 100% on days 7 and 
14 and > 99% from day 21 until the end of the study 56 
days after treatment.
Cultures of pooled fecal samples performed at day 
0 contained Cyathostomum spp, Poteriostomum spp, Tri-
odontophorus spp, and Strongylus vulgaris. Cultures of 
fecal samples from 1 donkey at days 21 and 28 and from 
3 donkeys on day 35 until the end of the study and 
Figure 2—Mean ± SD eprinomectin concentration in hair sam-
ples collected from the application site (inverted triangles) and 
far from the application site (circles) in 8 donkeys at various times 
after topical administration (0.5 mg/kg) of a pour-on formulation 
licensed for use in cattle. Day of eprinomectin administration was 
designated as day 0.
 Day of study* 
Variable –3 0 7 14 21 28 35 42 49 56
Egg counts for 
  individual donkeys 
  (No. of eggs/
  g of feces)        
     Mean 1,204 1,361 0 0 0.8 2.5 5.8 3.3 3.3 5.0
     Range† 300–3,300 (0) 200–3,190 (0) — (12) — (12) 0–10 (11) 0–30 (11) 0–40 (9) 0–20 (9) 0–10 (8) 0–30 (8)
FECR (%) — — 100 100 99.9 99.8 99.6 99.7 99.7 99.6
     Upper CL — — — — 100 100 100 100 100 100
     Lower CL — — — — 99 98 98 99 99 99
*Day of topical administration of eprinomectin was designated as day 0. †Values in parentheses are the number of donkeys with an egg count 
of 0.
— = Not applicable. CL = Confidence limit.
Table 2—Strongyle egg counts and FECR after topical administration of eprinomectin (0.5 mg/kg) to 12 donkeys.
 Dosage Cmax  AUC
Species (µg/kg)  (ng/mL) Tmax (d)  (ng•d/mL) t1/2 (d) MRT (d) Reference
Donkey 500 14.17 3.38 129.44 6.33 8.95 —
Buffalo 500 2.7 1.44 11.43 NR 4.49 2
Cattle       
  Bos taurus 500 43.8 2.02 241.21 2.03 4.16 18
  Bos indicus 500 8.8 1.30 30.63 1.95 3.38 19
Sheep (Istrian Pramenka) 500 2.2 2.20 13.60 5.40 7.70 20
 1,000 5.3 1.50 33.70 12.20 9.00 20
Goat (Saanen) 500 2.2 0.75 8.24 2.44 2.67 21
 1,000 2.98 0.99 15.68 3.04 3.69 21
 500 5.6 2.55 72.31 7.46 9.42 22
Camel 500 1.8 1.50 6.26 NR 5.30 23
— = Not applicable; results determined in the present study. NR = Not reported.
Table 3—Plasma pharmacokinetic parameters for eprinomectin after topical administration in several 
animal species.
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from 4 donkeys on day 49 until the end of the study 
had few Cyathostomum spp larvae.
Plasma pharmacokinetic parameters of eprinomec-
tin for the donkeys of the present study were compared 
with those of other animal species following topical ad-
ministration2,18–23 (Table 3).
Discussion
The pharmacokinetic behavior of endectocides is 
considerably affected by the route of administration, 
formulation of the drug, and interspecies and interindi-
vidual variation.24 Although many studies25–31 have been 
performed to determine the pharmacokinetic behavior of 
endectocides in horses, there is little information on the 
plasma pharmacokinetics of endectocides in donkeys.32,33
Large variations in pharmacokinetics are evident 
among animal species after topical administration of 
eprinomectin as a result of anatomic and physiologic 
variation among animal species and irregular absorp-
tion of drug from the site of application associated with 
differences in coat length and hair density. In the pres-
ent study, the plasma concentrations and systemic ex-
posure of eprinomectin in donkeys were lower, whereas 
t
1/2
 and MRT were longer, compared with results for 
cattle18 administered eprinomectin at the same dosage. 
The origin of this difference is probably self-licking or 
licking other cattle that make the systemic availabil-
ity and plasma disposition variable and unpredictable, 
considering that no licking behavior was observed in 
the donkeys of the present study. In contrast to cattle, 
donkeys typically do not have self-licking behavior. 
Large differences between animals that lick and those 
that do not lick have been observed after topical admin-
istration of ivermectin or doramectin.34–36 Prevention of 
licking results in an extended terminal plasma t
1/2
 and 
in a lower systemic availability and fecal excretion of 
ivermectin in cattle.34
The pharmacokinetic behavior of eprinomectin in 
the present study after topical administration in don-
keys differed substantially from that in buffalo, sheep, 
goats, and camels (Table 3). Plasma concentration and 
systemic exposure of eprinomectin are much higher in 
donkeys, compared with those in the aforementioned 
animals, after topical administration. Although the rea-
son for the higher systemic exposure of eprinomectin 
in donkeys, compared with systemic exposure in other 
animal species, is unclear, the relatively high AUC in 
donkeys can be explained by a low plasma clearance 
or a relatively high bioavailability. Differences among 
animal species may relate to histologic and physiologic 
variations in structure of the skin and coat because it 
has been reported that the comparative number of cell 
layers, epidermal and corneum thickness, and blood 
flow to various parts of the skin differ among animal 
species.37 Moreover, hair follicle density and length 
of coat and the secretions from sweat and sebaceous 
glands are important variables for differences in drug 
absorption from the skin among animal species.38
The pharmacokinetic disposition of eprinomectin 
after topical administration in donkeys in the present 
study differed substantially from that of ivermectin re-
ported in horses31 at the same dosage and via the same 
route of administration. In the study reported here, a 
shorter Tmax (3.38 days), higher Cmax (14.17 ng/mL), 
and larger AUC (129.4 ng•d/mL) but shorter t
1/2
 (6.33 
days) and MRT (8.95 days) of eprinomectin were de-
tected in donkeys, compared with those detected after 
topical administration of ivermectin in horses (Tmax, 
4.33 days; Cmax, 4.29 ng/mL; AUC, 59.93 ng•d/mL; 
t1/2, 7.18 days; and MRT, 11.8 days).
31 The origin of this 
difference is unclear. Differences in the physical-chem-
ical structure between eprinomectin and ivermectin are 
the most likely reason because the endectocides have 
structural features that affect their pharmacokinetics. 
Substitution of the C-4 hydroxyl group with acyl, ami-
no, or thio groups improves the solubility and tissue 
distribution of avermectins, and this feature has been 
used for the epiacetyl amino substitution in eprinomec-
tin that retains and enhances the potency and spectrum 
of activity of this avermectin, which is effectively ab-
sorbed percutaneously and possesses a very low plas-
ma-to-milk partitioning ratio (0.17) that permits use 
in lactating dairy cattle39 (plasma-to-milk partitioning 
ratio for ivermectin in dairy cattle, 0.76).40 The low 
plasma-to-milk partition coefficient of eprinomectin 
suggests that structural conformation independent of 
absolute lipid solubility may be important for trans-
fer between the mammary gland capillary vasculature 
and alveolar epithelium. Moreover, differences in the 
physiologic and histologic structure of the skin or coat 
between donkeys and horses probably play important 
roles for transfer of the drug from the surface of the 
skin into the systemic circulation.
Despite these differences in pharmacological as-
sessment, eprinomectin has a broad spectrum of activity 
against endoparasites and ectoparasites in several large 
animal species. Regarding the intestinal nematodes, 
eprinomectin has high efficacy in cattle,39,41 sheep,42 
and goats.43 There are scarce data on the use of aver-
mectins in donkeys. Furthermore, to our knowledge, 
no data regarding the pharmacokinetic behavior and 
parasitological efficacy of eprinomectin against intesti-
nal strongyles in donkeys have been reported.
Relatively high concentrations and slow degrada-
tion of eprinomectin in hair samples collected from the 
application site were observed in the present study. In 
addition, detectable concentrations in hair samples col-
lected far from the application site were likely attrib-
utable to the excretion of eprinomectin by sebaceous 
glands (after absorption of a fraction of eprinomectin). 
It has been found that moxidectin is excreted by seba-
ceous glands.44 These results suggest that eprinomectin 
was available at the skin surface for a long period after 
topical administration and thus probably provided long 
persistence of efficacy against ectoparasites in donkeys. 
In addition, the t
1/2
 for concentrations in the hair at the 
application site was much longer (27.06 days), com-
pared with the t
1/2
 for plasma (6.33 days). This lack of 
parallelism between the 2 curves could suggest that the 
t
1/2
 of absorption is not the limiting rate for eprinomec-
tin disposition in donkeys.
Relatively high drug concentrations detected 
in the coat of donkeys may result in potential con-
tamination to humans, especially if the donkeys are 
used for milking. The people who milk the donkeys 
should be aware of this concern and take precautions 
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to prevent cross-contamination after topical drug 
administration.
Analysis of results of the present study indicated 
that topical application of eprinomectin at the dosage 
recommended for cattle (0.5 mg/kg) did not cause safe-
ty issues in donkeys. Eprinomectin was tolerated well 
by all the donkeys, with no adverse reactions following 
treatment.
The present study indicated that the plasma con-
centration of eprinomectin after topical administra-
tion is relatively greater in donkeys, compared with 
that in other animal species (Table 3). Eprinomectin 
was highly effective against intestinal strongyles in 
all the donkeys, and higher FECRs were observed 
after topical application. The persistence of epri-
nomectin on the coat at the application site and far 
from the application site after topical administration 
may prolong the efficacy against ectoparasites, espe-
cially for nonbloodsucking parasites such as biting 
lice. Considering the pharmacokinetic disposition 
and anthelmintic efficacy, topical administration 
of eprinomectin could be used for the control and 
treatment of parasitic diseases in donkeys. Neverthe-
less, further studies are required to determine the milk 
excretion and milk-withdrawal time for eprinomectin 
after topical administration in milking donkeys.
a. Eprinex pour-on formulation, 0.5% wt/vol, Merial, Assago, Italy.
b. Sigma Chemical Co, St Louis, Mo.
c. AccuBOND, 200 mg/3 mL, Agilent, Waldron, Germany.
d. Maxi-dry Plus, Heto Lab Equipment, Allerød, Denmark.
e. 1100 Series, Agilent, Waldron, Germany.
f. Luna, Phenomenex, Macclesfield, Cheshire, England.
g. WinNonlin, version 5.2, Pharsight Corp, Mountain View, Calif.
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